40.00MMarket Cap-1045P/E (TTM)
4.3000High4.1200Low128.83KVolume4.2600Open4.3000Pre Close519.78KTurnover1.91%Turnover RatioLossP/E (Static)9.57MShares12.000052wk High-3.40P/B28.16MFloat Cap2.210052wk Low--Dividend TTM6.74MShs Float769.9000Historical High--Div YieldTTM4.19%Amplitude2.2100Historical Low4.0340Avg Price1Lot Size
NRX Pharmaceuticals Stock Forum
NEWS
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to ...
Update
good run today
good
With positive data from this study and FDA comment, NRx becomes eligible to receive the balance of its first milestone (an additional $4 million) from partners...
Watching
7 MINUTES AGO, 8:30 AM EDT
VIA PR NEWSWIRE
• Data transferred for independent statistical analysis
• Top-line data expected in April 2024
Lots of great info here!
RADNOR, Pa., April 1, 2024
Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend
-- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share improvement in negative earnings. Additions to working capital of $8 million in Q1 2024.
-- Company forecasts first commercial revenue in 2024 from sales of ke...
Before RS, either they should be a huge news to shoot up the price or else have to wait till RS completion
Plan to defeat naked short selling!
The Company announced a proposal to simultaneously change the CUSIP under which the Company's shares are traded, together with changing the name of the Company to NRx Therapeutics, Inc. The Company plans to accompany these actions with a ...
No comment yet